Dec 21 (Reuters) - CSL Ltd (CSL) :
- CO AND ARCTURUS THERAPEUTICS' ARCT-154 DEMONSTRATES NON-INFERIORITY TO ORIGINAL STRAIN AND SUPERIOR IMMUNOGENICITY TO OMICRON BA.4/5 VARIANT
- DATA FOLLOW APPROVAL OF WORLD'S FIRST SELF-AMPLIFYING MESSENGER RNA (SA-MRNA) COVID-19 VACCINE FOR ADULTS BY JAPAN MOH, LABOR AND WELFARE
- ARCT-154 STUDY IS ONGOING & WILL CONTINUE TO COLLECT SAFETY DATA AND ASSESS DURABILITY OF IMMUNE RESPONSE IN PARTICIPANTS
(([email protected];))
News: CSL CSL and Arcturus Therapeutics' Arct-154 Demonstrates Non-Inferiority To Original Strain
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$255.31 |
Change
-2.070(0.80%) |
Mkt cap ! $123.6B | |||
| Open | High | Low | Value | Volume |
| $256.32 | $256.50 | $252.60 | $171.9M | 674.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6 | $255.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.83 | 104 | 1 |
View Market Depth
| Last trade - 16.14pm 21/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |